Bial Drug Tragedy: French Senate To Look Afresh At Clinical Trial Rules
This article was originally published in SRA
Executive Summary
A French Senate committee has intervened in the debate over the Phase I study of a new drug that caused the death of one volunteer and led to the hospitalization of several others, saying that it plans to meet with the government inspectors who visited the site in Rennes to discuss their findings, with a view to looking afresh at the legislation governing clinical trials1.
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.